Back

Germline predisposition to oncogenic alkylating damage in colorectal cancer

Gurjao, C.; Cazaubiel, J.; Tan, C.; Reardon, B.; Hofree, M.; Ugai, T.; Meyerhardt, J. A.; Nowak, J. A.; Giovannucci, E. L.; Townsend, J. P.; Ogino, S.; Giannakis, M.

2025-07-02 oncology
10.1101/2025.06.30.25330572
Show abstract

BackgroundRed meat consumption is a risk factor for colorectal cancer (CRC) and has been linked to tumor alkylating DNA damage. rs16906252-T is a cis expression quantitative trait locus (eQTL) variant associated with silencing of MGMT, a central alkylating damage repair gene. We hypothesize that rs16906252-T carriers are predisposed to alkylating damage mutations. MethodsWe conducted mutational signature deconvolution of CRC whole-exome sequencing data from The Cancer Genome Atlas (TCGA, n = 540), the Nurses Health Studies/ Health Professional Follow-up Study (NHS/HPFS, n = 900) as well as non-western samples from the Pan-Cancer Analysis of Whole Genomes (COCA-CN, n = 295); and examined the relationship of rs16906252-T with putative alkylation-dependent tumor mutations. Leveraging lifestyle data from NHS/HPFS, we also investigated the interaction between red meat consumption and rs16906252-T. ResultsAmong CRC patients, rs16906252-T carriers exhibited higher tumor alkylating damage compared to non-carriers. In the general population, rs16906252-T is largely absent in individuals with East Asian ancestries, and we consistently find a negligible contribution of alkylating damage in CRC patients with East Asian ancestries. We show that the alkylating mutational signatures carcinogenicity is mainly mediated by KRAS G12D and G13D mutations. We also observe a synergistic effect of rs16906252-T with high pre-diagnosis red meat intake for tumor alkylating damage. ConclusionsMGMT rs16906252-T carriers are predisposed to CRC oncogenic alkylating damage which is potentiated by red meat intake. ImpactOur results support a causal relationship between red meat and CRC and can lead to tailored dietary and screening guidelines for CRC prevention.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Cancer Epidemiology, Biomarkers & Prevention
based on 14 papers
Top 0.1%
11.5%
2
Nature Communications
based on 483 papers
Top 7%
10.5%
3
Cancers
based on 57 papers
Top 2%
7.8%
4
Scientific Reports
based on 701 papers
Top 33%
5.5%
5
Nature
based on 58 papers
Top 1.0%
4.6%
6
British Journal of Cancer
based on 22 papers
Top 1%
3.0%
7
Clinical Cancer Research
based on 22 papers
Top 1%
3.0%
8
Nature Genetics
based on 72 papers
Top 4%
3.0%
9
Clinical Epigenetics
based on 21 papers
Top 0.3%
3.0%
50% of probability mass above
10
eLife
based on 262 papers
Top 8%
2.9%
11
Gut
based on 17 papers
Top 1%
2.6%
12
PLOS ONE
based on 1737 papers
Top 83%
2.5%
13
International Journal of Cancer
based on 18 papers
Top 0.8%
2.4%
14
Frontiers in Oncology
based on 34 papers
Top 4%
2.4%
15
Cancer Medicine
based on 17 papers
Top 2%
1.8%
16
Aging
based on 18 papers
Top 1%
1.8%
17
Proceedings of the National Academy of Sciences
based on 100 papers
Top 7%
1.6%
18
Communications Biology
based on 36 papers
Top 2%
1.6%
19
JNCI: Journal of the National Cancer Institute
based on 13 papers
Top 1.0%
1.6%
20
BMC Cancer
based on 21 papers
Top 3%
1.6%
21
JCO Precision Oncology
based on 11 papers
Top 2%
1.4%
22
Leukemia
based on 11 papers
Top 1%
1.2%
23
BMC Medicine
based on 155 papers
Top 21%
0.8%
24
Journal for ImmunoTherapy of Cancer
based on 14 papers
Top 2%
0.8%
25
npj Precision Oncology
based on 14 papers
Top 4%
0.8%
26
International Journal of Radiation Oncology*Biology*Physics
based on 13 papers
Top 3%
0.8%
27
Science
based on 46 papers
Top 8%
0.7%
28
The American Journal of Human Genetics
based on 77 papers
Top 7%
0.7%
29
iScience
based on 74 papers
Top 8%
0.7%